Skip to main content

Table 1 Molecular features of the human CRC cell lines in comparison with their sensitivity to niraparib, 5-fluorouracil oxaliplatin or SN38 monotherapy

From: Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

     

IC50 (μM)

Cell line

KRAS/BRAF status

MSI status

ATM and BRCA1/2 status

CMS

Niraparib

5FU

Oxaliplatin

SN38

HCT15

KRAS mut

MSI

ATM mut

BRCA2 mut

CMS1

1.4

6.2

0.3

0.006

LOVO

KRAS mut

MSI

 

CMS1

1.6

2

0.1

0.01

LIM1215

RAS/BRAF wt

MSI

ATM mut

CMS1

2.3

5.1

0.8

0.005

SW48

RAS/BRAF wt

MSI

BRCA2 mut

CMS1

4.3

5.3

0.2

0.001

SW1116

KRAS mut

MSS

 

CMS2

> 10

2.7

1

> 1

LS1034

KRAS mut

MSS

 

CMS2

6.2

1.5

0.1

0.02

SW403

KRAS mut

MSS

 

CMS2

6.3

3.7

2.7

0.008

SW948

KRAS mut

MSS

ATM mut

CMS3

2.8

14.5

0.1

0.06

WiDr

BRAF mut

MSS

 

CMS3

8.5

32

0.8

0.003

HCT116

KRAS mut

MSI

ATM mut

CMS4

1.4

2.2

0.25

0.005

SW480

KRAS mut

MSS

ATM mut

CMS4

2.1

5.4

0.4

0.005

CACO2

RAS/BRAF wt

MSS

 

CMS4

8.6

2.2

0.1

0.01

  1. MSI Microsatellite instable, MSS Microsatellite stable, CMS Consensus molecular subtype, wt wild type, mut Mutant. For ATM and BRCA2, only mutations predicted to be pathogenic are included